Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Chih-Hsin Yang

Showing results (1-10 of 286) with videos related to

Pageof 29
Sort By:
Future Oncology (London, England)|February 16, 2023
Afatinib for the treatment of non-small-cell lung cancer with unusual EGFR mutations: a plain language summaryJames Chih-Hsin Yang
The Lancet. Oncology|May 4, 2013
A selective ALK inhibitor in ALK-rearranged patientsJames Chih-Hsin Yang
The Lancet. Oncology|April 13, 2019
Bevacizumab in EGFR-positive NSCLC: time to change first-line treatment?James Chih-Hsin Yang
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 17, 2012
Small-cell lung cancer treatment: where is the target?James Chih-Hsin Yang
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2014
Reply to E.R. Haspinger et alJames Chih-Hsin Yang, Lecia V Sequist
Translational Lung Cancer Research|March 26, 2015
Front-line erlotinib in unselected patient with advanced NSCLC followed by standard chemotherapy with gemcitabine and cisplatin - TORCH studyBin-Chi Liao, James Chih-Hsin Yang
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 24, 2021
Active or Attractive? Oral Antiangiogenesis Therapy Plus EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant NSCLCBin-Chi Liao, James Chih-Hsin Yang
Drugs|December 24, 2010
Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutationsChia-Chi Lin, James Chih-Hsin Yang
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2014
Reply to F. De Marinis et alJames Chih-Hsin Yang, Lecia V Sequist
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 27, 2018
Real-World or Controlled Clinical Trial Data in Real-World PracticeTing-Hui Wu, James Chih-Hsin Yang
Pageof 29

Showing results (1-10 of 286) with videos related to

Sort By:
Pageof 29
Future Oncology (London, England)|February 16, 2023
Afatinib for the treatment of non-small-cell lung cancer with unusual EGFR mutations: a plain language summaryJames Chih-Hsin Yang
The Lancet. Oncology|May 4, 2013
A selective ALK inhibitor in ALK-rearranged patientsJames Chih-Hsin Yang
The Lancet. Oncology|April 13, 2019
Bevacizumab in EGFR-positive NSCLC: time to change first-line treatment?James Chih-Hsin Yang
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 17, 2012
Small-cell lung cancer treatment: where is the target?James Chih-Hsin Yang
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2014
Reply to E.R. Haspinger et alJames Chih-Hsin Yang, Lecia V Sequist
Translational Lung Cancer Research|March 26, 2015
Front-line erlotinib in unselected patient with advanced NSCLC followed by standard chemotherapy with gemcitabine and cisplatin - TORCH studyBin-Chi Liao, James Chih-Hsin Yang
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 24, 2021
Active or Attractive? Oral Antiangiogenesis Therapy Plus EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant NSCLCBin-Chi Liao, James Chih-Hsin Yang
Drugs|December 24, 2010
Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutationsChia-Chi Lin, James Chih-Hsin Yang
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2014
Reply to F. De Marinis et alJames Chih-Hsin Yang, Lecia V Sequist
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 27, 2018
Real-World or Controlled Clinical Trial Data in Real-World PracticeTing-Hui Wu, James Chih-Hsin Yang
Pageof 29